Wells Fargo Initiates Progyny(PGNY.US) With Buy Rating, Announces Target Price $37
Wells Fargo has initiated coverage on Progyny (PGNY.US) with a "Buy" rating. The firm has set a price target of $37 for the company's shares. This indicates a positive outlook from Wells Fargo regarding Progyny's future stock performance.
Bank of America Corp DE Grows Stake in Progyny, Inc. $PGNY
Bank of America Corp DE significantly increased its stake in Progyny, Inc. (NASDAQ:PGNY) by 75.3% in the first quarter, now owning 1.19 million shares valued at $20.2 million. This comes as Progyny reported strong quarterly earnings, beating analyst expectations, and authorized a $200 million share repurchase program. Despite some insider selling, analysts maintain a "Moderate Buy" rating with a consensus target price of $34.10.
Progyny Sees Utilization Rebound as Early Renewals De-Risk Outlook
Progyny (NASDAQ: PGNY) anticipates a rebound in fertility-treatment utilization after a summer slowdown, with September appointment trends returning to earlier levels. The company's full-year outlook is de-risked by early renewal commitments and strong new-client acquisition, targeting at least 1 million new covered lives. Progyny also sees expanding growth opportunities, including replacement business, health-plan partnerships, and new offerings like Progyny Select, which has increased its estimated addressable market to 155 million lives.
Progyny Sees Utilization Rebound as Early Renewals De-Risk Outlook
Progyny's CEO, Pete Anevski, announced that the company anticipates a rebound in member engagement and utilization after a more significant summer slowdown. Early renewal commitments and new client acquisitions have bolstered management's confidence in the company's financial outlook for the remainder of the year. Progyny also reported stronger early new-business commitments and an expansion of its client base across numerous industries, de-risking its renewal rates for the upcoming year.
Discipline and Rules-Based Execution in PGNY Response
This article provides an AI-generated analysis for Progyny Inc. (NASDAQ: PGNY), highlighting a weak near and mid-term sentiment that could challenge a positive long-term outlook. It details specific trading strategies for various risk profiles, including long and short positions with defined entry points, targets, and stop losses. The analysis also includes multi-timeframe signal analysis, emphasizing support and resistance levels.
Royal Bank of Canada Has $3.71 Million Stock Position in Progyny, Inc. $PGNY
Royal Bank of Canada significantly increased its stake in Progyny, Inc. (NASDAQ:PGNY) by 98% in the first quarter, now owning 218,434 shares valued at $3.71 million. Other institutional investors also adjusted their positions, and 94.93% of Progyny stock is held by institutional investors and hedge funds. Despite some insider selling, analysts generally have a "Moderate Buy" rating with an average target price of $34.10, and the company has authorized a $200 million share repurchase program, suggesting management views the stock as undervalued.
Truist Financial Maintains Progyny(PGNY.US) With Buy Rating, Announces Target Price $36
Truist Financial has reiterated its Buy rating on Progyny (PGNY.US) and set a target price of $36. This indicates the firm's continued confidence in the company's stock performance.
Truist Adjusts Price Target on Progyny to $36 From $33, Maintains Buy Rating
Truist Securities has increased its price target for Progyny (PGNY) to $36 from $33, while reiterating a Buy rating on the stock. This adjustment reflects a positive outlook on the company's valuation.
Truist Adjusts Price Target on Progyny to $36 From $33, Maintains Buy Rating
Truist has increased its price target for Progyny (PGNY) from $33 to $36, while reiterating a Buy rating on the stock. This adjustment follows Progyny's Q2 2026 earnings report, where the company exceeded revenue estimates. Progyny, a benefit management company specializing in fertility and family building solutions, also provided optimistic guidance for its Q3 2026 revenue and adjusted EPS.
PGNY Maintains Rating by Barclays -- Price Target Lowered to $30
Barclays has maintained an Equal-Weight rating on Progyny (PGNY) but lowered its price target to $30 from $34. Despite this, Progyny is considered undervalued by GuruFocus with a GF Value™ of $28.56 against its current price of $26.55, and boasts a strong GF Score™ of 91/100, indicating robust financial health and growth potential. However, a mixed sentiment from institutional investors and significant insider selling suggest caution for potential investors.
Sei Investments Co. Decreases Stake in Progyny, Inc. $PGNY
Sei Investments Co. reduced its stake in Progyny, Inc. by 46.9% in the first quarter, selling over 71,000 shares and retaining a holding valued at $1.37 million. Despite this reduction, institutional investors collectively own 94.93% of Progyny, which has a consensus "Moderate Buy" rating and an average price target of $34.20 from analysts. The company also announced a $200 million stock repurchase program, while insiders have sold a significant number of shares recently.
Progyny Drops 5.4% Amid Sector-Wide Selling
Progyny, Inc. experienced a 5.4% decline, closing at $26.34, as part of a sector-wide selloff affecting healthcare plan providers. The drop, accompanied by similar losses in peer companies like ALHC and MRDH, suggests broader investor repositioning rather than company-specific news. Investors are advised to monitor whether this sector weakness persists or if individual company fundamentals begin to differentiate performance.
Progyny, Inc. $PGNY Shares Sold by Janus Henderson Group PLC
Janus Henderson Group PLC significantly reduced its stake in Progyny, Inc. (NASDAQ:PGNY) by 84.1% in the first quarter, selling over 200,000 shares. Despite this, institutional investors collectively hold 94.93% of the company's stock, and analyst sentiment remains positive with a "Moderate Buy" consensus and a $34.20 price target. Progyny also announced a $200 million share repurchase program, indicating management believes the stock is undervalued.
Why Progyny (PGNY) Shares Are Sliding Today
Progyny's shares dropped by 4.5% after the company issued a weaker-than-expected forecast for the upcoming quarter and lowered its full-year revenue and EBITDA guidance, despite beating second-quarter earnings estimates. This disappointing outlook overshadowed strong Q2 results and previous analyst upgrades, leading to a significant sell-off. The stock is currently trading 12.4% below its 52-week high, and investors who bought 5 years ago would have seen a significant loss.
Quantinno Capital Management LP Grows Position in Progyny, Inc. $PGNY
Quantinno Capital Management LP significantly increased its holdings in Progyny, Inc. (NASDAQ:PGNY) by 382.6
Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
Progyny, Inc. (Nasdaq: PGNY) announced that CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, at 3:30 p.m. ET. A live audiocast and replays will be available on the company's investor relations website. Progyny is a global leader in women's health and family building solutions, recognized for its comprehensive and inclusive benefit solutions.
Progyny, Inc. 2026: Revenue $350.51M, EPS $0.34— 10-Q Summary
Progyny, Inc. reported strong second-quarter 2026 results, with revenue reaching $350.51 million and diluted EPS of $0.34, showcasing modest top-line growth and significant profitability improvement year-over-year. The company expanded its client base to over 600, covering approximately 7.2 million lives, and saw improved gross margins due to care management efficiencies.
Progyny, Inc. Stock 12‑Month Price Target Cut to $33.82, Implies 12% Upside
Progyny, Inc.'s average stock price target has been reduced to $33.82 from $34 by 11 analysts, with individual forecasts ranging from $27 to $40 per share. This updated target suggests a potential 12% upside based on the Aug. 6 closing price. The consensus rating for Progyny remains a "Buy" among the 11 covering analysts.
Progyny Posts Record Q2 Results, Expands Client Base
Progyny reported record second-quarter 2026 results with revenue of $350.5 million, up 5.3% year-over-year, and a 13% increase in gross profit to $89.3 million, despite losing a large client. The company also saw net income rise to $28.1 million and adjusted EBITDA to $62.1 million, driven by efficiency gains. Progyny expanded its client base to 604 customers and repurchased 1.2 million shares, reinforcing its position in the employer-sponsored women's health benefits market, leading TipRanks' AI Analyst, Spark, to rate the stock as "Outperform."
Why Progyny Stock Plunged, Then Gradually Recovered Today
Progyny's stock initially dropped by 6% after its second-quarter earnings report, despite sales rising 5% and adjusted earnings per share increasing by 15%, both exceeding Wall Street expectations. The market reacted negatively to management's conservative Q3 revenue growth guidance of 7% to 11%. However, the company's solid Q2 performance, including expanding gross profit margins and the introduction of its new "Progyny Select" offering for smaller employers, suggests a positive long-term outlook, leading to a gradual recovery in the stock price.
Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
Progyny, Inc. announced that its CEO, Pete Anevski, will present at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 3:30 p.m. ET. The presentation will be accessible via a live audiocast and replay on Progyny’s investor relations website. Progyny is a leading company in women's health and family building solutions, recognized for its comprehensive approach to improving health outcomes and reducing healthcare costs.
Progyny CEO’s Aug. 11 Boston session will have a live audiocast
Progyny, Inc. (Nasdaq: PGNY) announced that its CEO, Pete Anevski, will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA, on Tuesday, August 11, 2026, at 3:30 p.m. ET. Live audiocasts and replays of the webcasted session will be accessible via the Events and Presentations section of Progyny’s investor relations website. The presentation will offer insights into Progyny's role as a leader in women’s health and family building solutions.
Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
Progyny, Inc. announced that its CEO, Pete Anevski, will present at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 3:30 p.m. ET. The presentation will be audiocast live and available for replay on Progyny's investor relations website. Progyny is a global leader in women's health and family building solutions.
Progyny, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:PGNY) 2026-08-07
Progyny, Inc. has published its Q2 2026 earnings call presentation. The company reported EPS of $0.55, beating estimates by $0.03, and revenue of $350.51 million, surpassing expectations by $1.86 million, representing a 5.30% year-over-year increase. This article provides access to the slide deck presented during the earnings call.
Progyny Inc (PGNY) (Q2 2026) Earnings Call Highlights: Record Revenue and EBITDA Amid Strategic ...
Progyny Inc (PGNY) reported record revenue, gross profit, and adjusted EBITDA for Q2 2026, with revenue increasing 5.3% year-over-year. The company provided full-year 2026 guidance, projecting revenue between $1.36 billion and $1.385 billion, and reaffirmed strong selling season momentum and client retention. Despite a slight downward adjustment in Q3 guidance due to summer seasonality, Progyny continues to generate strong cash flow and execute significant share repurchases.
Progyny, Inc. Announces Second Quarter 2026 Results
Progyny, Inc. reported strong second-quarter 2026 financial results, with record quarterly revenue of $350.5 million, gross profit of $89.3 million, and Adjusted EBITDA of $62.1 million. The company's CEO, Pete Anevski, highlighted robust member engagement and strong momentum in the selling season, while CFO Mark Livingston emphasized gross margin expansion and effective conversion of Adjusted EBITDA to operating cash flow. Progyny also provided financial guidance for the third quarter and full year 2026, projecting continued growth in revenue and earnings, and announced the repurchase of over 2 million shares under its current authorization.
Progyny Q2 2026 earnings: Margin expansion lifts profit faster than revenue
Progyny (Nasdaq: PGNY) reported Q2 2026 revenue of $350.5 million, a 5.3% year-over-year increase, and diluted EPS of $0.34, significantly up from $0.19 in Q2 2025. The company's profit growth outpaced revenue growth due to gross-margin expansion and lower stock-based compensation, despite a decline in quarterly operating cash flow. Management provided guidance for Q3 and full-year 2026, anticipating a seasonal slowdown in Q3 but strong selling-season momentum.
Earnings call transcript: Progyny beats Q2 2026 estimates, shares sink after hours
Progyny reported strong Q2 2026 results, beating adjusted EPS and revenue estimates with $0.55 per share and $350.51 million, respectively. Despite record financial performance, shares fell 15.59% in after-hours trading due to management's comments on a more pronounced summer slowdown impacting Q3 guidance. The company reaffirmed its full-year revenue and adjusted EPS guidance, maintaining confidence in its long-term growth trajectory and ability to add over 1 million new lives in 2026.
Progyny, Inc. Announces Second Quarter 2026 Results
Progyny, Inc. announced strong financial results for the second quarter of 2026, with revenue increasing by 5.3% to $350.5 million and net income rising to $28.1 million. The company reported record quarterly revenue, gross profit, and Adjusted EBITDA, driven by high member engagement and successful selling season activity. Progyny also returned value to shareholders by repurchasing over 2 million shares.
(PGNY) Progyny, Inc. Expects Q3 Revenue Range $335.0M - $345.0M
Progyny, Inc. (PGNY) announced its revenue expectations for the third quarter, projecting a range of $335.0 million to $345.0 million. This announcement follows their second-quarter earnings report, where the company posted revenues of $350.5 million, exceeding FactSet's estimate of $348.6 million, and an adjusted EPS of $0.55 per share, also above the $0.52 estimate. Progyny specializes in fertility and family building benefits solutions for employers in the United States.
Pacer Advisors Inc. Buys 144,073 Shares of Progyny, Inc. $PGNY
Pacer Advisors Inc. significantly increased its stake in Progyny, Inc. (NASDAQ:PGNY) by 49.4% in the first quarter, acquiring 144,073 additional shares and bringing their total holdings to 435,558 shares valued at approximately $7.4 million. This comes as Progyny exceeded first-quarter earnings expectations with an EPS of $0.50 against a $0.26 consensus, despite a 26.4% year-over-year revenue decline. The company also authorized a $200 million share-repurchase program, with analysts maintaining a "Moderate Buy" consensus and an average price target of $33.25.
FMR LLC and Abigail Johnson report 8.9% Progyny (PGNY) beneficial stake
FMR LLC and Abigail Johnson have reported a beneficial ownership stake of 8.9% in Progyny, Inc. (PGNY), according to a Schedule 13G/A SEC filing. This translates to 7,004,279.53 shares beneficially owned as of June 30, 2026. FMR LLC holds sole voting power over 7,003,929 shares and sole dispositive power over all reported shares, while Abigail P. Johnson has sole dispositive power over the same number of shares but no voting power.
Progyny, Inc. $PGNY Shares Bought by Segall Bryant & Hamill LLC
Segall Bryant & Hamill LLC significantly increased its stake in Progyny, Inc. (NASDAQ:PGNY) during the first quarter, now holding 82,198 shares valued at approximately $1.4 million. This move is part of a broader trend of institutional investors owning a substantial 94.93% of the company. Analysts maintain a "Moderate Buy" rating for Progyny, with an average price target of $33.25, following a quarter where the company exceeded EPS estimates despite a year-over-year revenue decline, and authorized a $200 million share repurchase program.
What To Expect From Progyny’s (PGNY) Q2 Earnings
Progyny (PGNY) is set to announce its Q2 earnings, with analysts expecting a 4.7% year-on-year revenue growth. The company previously beat revenue and EPS expectations last quarter. Investors are looking at peer performance, with CVS Health and Centene also reporting positive revenue growth in their Q2 results.
Progyny, Inc. (PGNY) Stock Analysis: Unpacking Growth Potential With A 7.83% Upside
Progyny, Inc. (PGNY) is a healthcare company focused on fertility, family building, and women's health benefits, currently trading at $31.53. The company shows strong financial health with a 14.94% return on equity and over $200 million in free cash flow, reinvesting profits instead of issuing dividends. Analysts are optimistic, with a consensus "Buy" rating and an average target price of $34.00, suggesting a 7.83% upside potential.
Progyny Inc (PGNY) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Progyny Inc (PGNY), highlighting its current earnings forecast score of 8.55 and a "Buy" analyst rating from 11 analysts. It details the average price target of $29.50, with a high of $33.00 and a low of $26.00, and includes expected revenue for the next quarter at $348.68 million and an EPS of $0.34. The article also provides a peer comparison in the Healthcare Providers & Services industry.
Earnings Preview: Progyny to Report Financial Results Post-market on August 06
Progyny (PGNY) is scheduled to release its financial results after the market closes on August 6th. The company is expected to report earnings of $0.05 per share, representing a 25% year-over-year increase, with revenue projected to rise 20.3% to $225.4 million. Investors will be looking for insights into the company's growth trajectory and future outlook.
PGNY|Progyny Inc|Price:31.360|Chg%:+0.600
This article from TradingKey provides a comprehensive stock analysis of Progyny Inc (PGNY), highlighting its strong fundamentals, high growth potential, and "Buy" rating from analysts. It notes that the company is fairly valued with high institutional ownership, although its technical performance doesn't fully support the current trend despite recent market outperformance. The analysis also details Progyny's business model focused on fertility and family building benefits solutions.
Progyny Number of Employees 2026 | Employee Count & Headcount Data
Progyny, Inc. (NASDAQ: PGNY) has approximately 866 total employees worldwide as of March 2026, marking a 53.8% growth from 563 employees in 2023. The company is actively hiring, though job postings declined by 23.9% in 2026. Most of its workforce is concentrated in the United States, and the average salary is $130,518.
Progyny (NASDAQ:PGNY): An Affordable Growth Play With Double-Digit Earnings Expansion
Progyny (NASDAQ:PGNY) is presented as an affordable growth opportunity due to its double-digit earnings expansion and reasonable valuation compared to its industry peers. The company demonstrates strong financial health with no debt and high profitability, operating in the growing fertility benefits management sector. While revenue growth is projected to decelerate, its fundamental strengths make it an attractive option for growth-oriented investors.
Barclays downgrades Progyny stock rating on utilization concerns By Investing.com
Barclays downgraded Progyny (PGNY) to Equalweight from Overweight despite raising its price target to $34.00, citing concerns about easing utilization trends in fertility clinics based on website traffic analysis. While the data still indicates a healthy environment, the slowdown in traffic growth suggests potential headwinds. Despite the cautious outlook from Barclays, other analysts have recently upgraded Progyny and the company's board has approved a $200 million share repurchase program, indicating mixed sentiment.
Progyny Inc (PGNY) Institutional Confidence
Progyny Inc (PGNY) received an institutional shareholding score of 10.00, placing it first in its industry. The institutional shareholding proportion increased by 8.18% quarter-over-quarter, reaching 113.05%. ETHSX is the largest institutional shareholder, holding 1.05M shares and increasing its holdings by 992.57%.
Barclays downgrades Progyny stock rating on utilization concerns
Barclays has downgraded Progyny (NASDAQ:PGNY) to Equalweight from Overweight despite raising its price target to $34.00, citing concerns about easing utilization trends in fertility clinics based on proprietary website traffic analysis. The analysis showed a deceleration in website traffic growth, suggesting potential headwinds, although the InvestingPro data indicates the company remains undervalued with a market cap of $2.47 billion and a P/E ratio of 41.48. This cautious outlook contrasts with several recent analyst upgrades and a $200 million share repurchase program announced by Progyny.
Barclays downgrades Progyny stock rating on utilization concerns
Barclays downgraded Progyny (PGNY) to Equalweight from Overweight, raising its price target to $34, despite the stock's recent strong performance. The downgrade is based on proprietary analysis of fertility clinic website traffic, indicating a slowdown in utilization trends, which could present headwinds for the company. Despite these concerns, InvestingPro data suggests Progyny remains undervalued, and the company has seen other recent analyst upgrades and approved a $200 million share repurchase program.
Progyny Inc (PGNY) Balance Sheet
This article provides the detailed quarterly and annual balance sheets for Progyny Inc (PGNY), including financial data for assets, liabilities, and shareholders' equity across multiple fiscal quarters and years. It also includes an FAQ section defining key balance sheet metrics, differences between assets, liabilities, and equity, and current versus non-current items, directly answering questions about Progyny's latest cash, total liabilities, total assets, and shareholders' equity figures.
Progyny Inc (PGNY) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Progyny Inc (PGNY) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. Key financial data like market cap and P/E ratio are also presented.
PGNY|Progyny Inc|Price:31.190|Chg%:+0.490
Progyny Inc. (PGNY) is a benefit management company specializing in fertility and family building solutions, offering services through its Smart Cycle approach and an integrated pharmacy solution, Progyny Rx. The company covers approximately 6.7 million employees and partners across various industries. As of Q1 2026, institutional shareholding increased, and fertility benefit services were the primary revenue driver, generating $830.93 million.
PGNY|Progyny Inc|Price:31.190|Chg%:+0.490
This article provides an in-depth analysis of Progyny Inc. (PGNY), highlighting its strong fundamentals, high growth potential, and relatively fair valuation. It notes that institutional ownership is high and analysts widely rate the stock as a "Buy" with an upward trend expected in the medium term. Despite positive fundamentals, technical indicators suggest a sideways trading pattern between support and resistance levels.
Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report
Progyny, Inc. (Nasdaq: PGNY) will release its financial results for the second quarter of 2026 after the market closes on Thursday, August 6, 2026. The company will host a conference call on the same day at 4:45 p.m. Eastern Time to discuss the results. Full details for accessing the conference call and a replay are provided.
Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report
Progyny, Inc. (Nasdaq: PGNY) will release its second quarter 2026 financial results after the market closes on Thursday, August 6, 2026. The company will host a conference call at 4:45 p.m. Eastern Time on the same day to discuss the results. An audio replay and webcast of the call will be available for those unable to attend live.
